Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

Similar articles for PubMed (Select 23426000)

1.

Raising awareness of non-Hodgkin lymphoma in HIV-infected adolescents: report of 2 cases in the HAART era.

Zangari P, Santilli V, Cotugno N, Manno E, Palumbo G, Lombardi A, De Vito R, Tchidjou H, Baldassari S, Ariganello P, Pontrelli G, De Florio F, Palma P, Bernardi S.

J Pediatr Hematol Oncol. 2013 Apr;35(3):e134-7. doi: 10.1097/MPH.0b013e318282cef5.

PMID:
23426000
2.

The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era.

Vilchez RA, Finch CJ, Jorgensen JL, Butel JS.

Medicine (Baltimore). 2003 Mar;82(2):77-81.

PMID:
12640183
3.

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.

Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S; Swiss HIV Cohort.

J Natl Cancer Inst. 2005 Mar 16;97(6):425-32.

4.

Modern management of non-Hodgkin lymphoma in HIV-infected patients.

Mounier N, Spina M, Gisselbrecht C.

Br J Haematol. 2007 Mar;136(5):685-98. Epub 2006 Dec 1. Review.

PMID:
17229246
5.

AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.

Cheung MC, Pantanowitz L, Dezube BJ.

Oncologist. 2005 Jun-Jul;10(6):412-26. Review.

6.

HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.

Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K, Marcus R, de Vos J, Young AM, Tenant-Flowers M, Orkin C, Johnson M, Chilton D, Gribben JG, Bower M.

J Clin Oncol. 2012 Nov 20;30(33):4111-6. doi: 10.1200/JCO.2011.41.4193. Epub 2012 Oct 8.

7.

Changing pattern of primary cerebral lymphoma in the highly active antiretroviral therapy era.

Cingolani A, Fratino L, Scoppettuolo G, Antinori A.

J Neurovirol. 2005;11 Suppl 3:38-44. Review.

PMID:
16540454
8.

Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy.

Antinori A, Cingolani A, Alba L, Ammassari A, Serraino D, Ciancio BC, Palmieri F, De Luca A, Larocca LM, Ruco L, Ippolito G, Cauda R.

AIDS. 2001 Aug 17;15(12):1483-91.

PMID:
11504980
9.
10.
11.

[Non-Hodgkin lymphomas with systemic presentation in patients with HIV infection. Clinical and prognostic factors in a series evaluated before the introduction of the highly active antiretroviral therapy (HAART)].

Segura Huerta A, López Tendero P, Romera Barroso B, Yuste Izquierdo AL, Gironés Sarrió R, Pérez Fidalgo JA, Gómez Codina J, López Aldeguer J.

Rev Clin Esp. 2004 Jun;204(6):303-7. Spanish.

PMID:
15171891
13.

Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy.

Thirlwell C, Sarker D, Stebbing J, Bower M.

Clin Lymphoma. 2003 Sep;4(2):86-92. Review.

PMID:
14556679
14.

Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma.

Simonelli C, Zanussi S, Cinelli R, Dal Maso L, Di Gennaro G, D'Andrea M, Nasti G, Spina M, Vaccher E, De Paoli P, Tirelli U.

Clin Infect Dis. 2003 Sep 15;37(6):820-7. Epub 2003 Aug 28.

15.

Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.

Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B, Straus D; AIDS Malignancy Consortium.

J Clin Oncol. 2001 Apr 15;19(8):2171-8.

PMID:
11304769
17.

Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study.

Schommers P, Wyen C, Hentrich M, Gillor D, Zoufaly A, Jensen B, Bogner JR, Thoden J, Wasmuth JC, Fätkenheuer G, Hoffmann C.

AIDS. 2013 Mar 13;27(5):842-5. doi: 10.1097/QAD.0b013e32835e069d.

PMID:
23574794
18.

Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.

Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, Costagliola D, Salmon D, Chêne G, Morlat P.

Cancer. 2004 Jul 15;101(2):317-24.

20.

Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma.

Baiocchi OC, Colleoni GW, Navajas EV, Duarte LC, Alves AC, Andrade AL, Kerbauy J, Oliveira JS.

Acta Oncol. 2002;41(2):192-6.

PMID:
12102166
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk